- Home
- LLY vs AZN Comparison
LLY vs AZN Comparison
Compare LLY & AZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LLY | AZN |
|---|---|---|
| Founded | 1876 | 1992 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 979.6B | 316.4B |
| IPO Year | 2007 | 1995 |
Fundamental Metrics
Financial Performance| Metric | LLY | AZN |
|---|---|---|
| Price | $1,177.85 | $155.83 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 19 | 1 |
| Target Price | ★ $1,218.84 | N/A |
| AVG Volume (30 Days) | 2.0M | ★ 3.7M |
| Earning Date | 04-30-2026 | 04-29-2026 |
| Dividend Yield | 0.81% | ★ 1.73% |
| EPS Growth | ★ 95.99 | N/A |
| EPS | ★ 16.19 | N/A |
| Revenue | ★ $65,179,000,000.00 | N/A |
| Revenue This Year | $27.15 | $10.34 |
| Revenue Next Year | $16.04 | $6.43 |
| P/E Ratio | $74.80 | ★ $31.91 |
| Revenue Growth | ★ 44.70 | N/A |
| 52 Week Low | $685.15 | $72.90 |
| 52 Week High | $1,249.45 | $212.71 |
Technical Indicators
Market Signals| Indicator | LLY | AZN |
|---|---|---|
| Relative Strength Index (RSI) | 49.87 | 34.17 |
| Support Level | $1,121.78 | $153.41 |
| Resistance Level | $1,182.73 | $209.98 |
| Average True Range (ATR) | 38.73 | 2.90 |
| MACD | 1.28 | -0.33 |
| Stochastic Oscillator | 53.67 | 12.59 |
Price Performance
Historical ComparisonAbout LLY Eli Lilly and Company
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
About AZN AstraZeneca PLC
A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.